These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36363500)

  • 1. Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study.
    Rizzo A; Salati M; Frega G; Merz V; Caputo F; Di Federico A; Palloni A; Carloni R; Ricci AD; Gadaleta-Caldarola G; Messina C; Spallanzani A; Gelsomino F; Benatti S; Luppi G; Melisi D; Dominici M; Brandi G
    Medicina (Kaunas); 2022 Oct; 58(11):. PubMed ID: 36363500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes.
    Lowery MA; Goff LW; Keenan BP; Jordan E; Wang R; Bocobo AG; Chou JF; O'Reilly EM; Harding JJ; Kemeny N; Capanu M; Griffin AC; McGuire J; Venook AP; Abou-Alfa GK; Kelley RK
    Cancer; 2019 Dec; 125(24):4426-4434. PubMed ID: 31454426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-line Chemotherapy Prolongs Survival in Real World Patients With Advanced Biliary Tract and Gallbladder Cancers: A Multicenter Retrospective Population-based Cohort Study.
    Zaidi A; Chandna N; Narasimhan G; Moser M; Haider K; Chalchal H; Shaw J; Ahmed S
    Am J Clin Oncol; 2021 Mar; 44(3):93-98. PubMed ID: 33350678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer.
    Peirce V; Paskow M; Qin L; Dadzie R; Rapoport M; Prince S; Johal S
    Target Oncol; 2023 Nov; 18(6):837-852. PubMed ID: 37751011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-line chemotherapy in biliary tract cancer: Outcome and prognostic factors.
    Schweitzer N; Kirstein MM; Kratzel AM; Mederacke YS; Fischer M; Manns MP; Vogel A
    Liver Int; 2019 May; 39(5):914-923. PubMed ID: 30716200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Third-line chemotherapy in advanced biliary cancers (ABC): pattern of care, treatment outcome and prognostic factors from a multicenter study.
    Salati M; Rizzo A; Merz V; Messina C; Francesco C; Gelsomino F; Spallanzani A; Ricci AD; Palloni A; Frega G; De Lorenzo S; Carotenuto P; Pettorelli E; Benatti S; Luppi G; Melisi D; Brandi G; Dominici M
    Expert Rev Gastroenterol Hepatol; 2022 Jan; 16(1):73-79. PubMed ID: 34890512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognosis and prognostic factors in patients with advanced biliary tract cancer depending on its anatomical location.
    Song BG; Park JK; Kim HS; Kim K; Park JK; Lee KH; Lee KT; Lee JK
    Scand J Gastroenterol; 2019 Jun; 54(6):740-745. PubMed ID: 31136212
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of FOLFIRINOX Chemotherapy with Other Regimens in Patients with Biliary Tract Cancers: a Retrospective Study.
    Kus T; Aktas G; Kalender ME; Sevinc A; Camci C
    J Gastrointest Cancer; 2017 Jun; 48(2):170-175. PubMed ID: 27714651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluoropyrimidine-based doublet chemotherapy as second-line treatment for advanced biliary tract cancer: a meta-analysis of ABC-06 and NIFTY.
    Rizzo A; Cusmai A; Giovannelli F; Acquafredda S; Rinaldi L; Misino A; Palmiotti G
    Expert Rev Gastroenterol Hepatol; 2022 Mar; 16(3):273-278. PubMed ID: 35220866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
    Moehler M; Maderer A; Schimanski C; Kanzler S; Denzer U; Kolligs FT; Ebert MP; Distelrath A; Geissler M; Trojan J; Schütz M; Berie L; Sauvigny C; Lammert F; Lohse A; Dollinger MM; Lindig U; Duerr EM; Lubomierski N; Zimmermann S; Wachtlin D; Kaiser AK; Schadmand-Fischer S; Galle PR; Woerns M;
    Eur J Cancer; 2014 Dec; 50(18):3125-35. PubMed ID: 25446376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and predictive factors for Taiwanese patients with advanced biliary tract cancer undergoing frontline chemotherapy with gemcitabine and cisplatin: a real-world experience.
    Wu CE; Chou WC; Hsieh CH; Chang JW; Lin CY; Yeh CN; Chen JS
    BMC Cancer; 2020 May; 20(1):422. PubMed ID: 32410631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-line treatments in advanced biliary tract cancer: systematic literature review of efficacy, effectiveness and safety.
    Khankhel ZS; Goring S; Bobiak S; Lamy FX; Nayak D; Garside J; Reese ES; Schoenherr N
    Future Oncol; 2022 Jun; 18(18):2321-2338. PubMed ID: 35387496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Outcomes of Gemcitabine, Cisplatin, and Nab-Paclitaxel Chemotherapy Regimen for Advanced Biliary Tract Cancer: A Propensity Score-Matched Analysis.
    Jung K; Park J; Jung JH; Lee JC; Kim J; Hwang JH
    Gut Liver; 2022 Sep; 16(5):798-805. PubMed ID: 35000934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin.
    Dierks J; Gaspersz MP; Belkouz A; van Vugt JLA; Coelen RJS; de Groot JWB; Ten Tije AJ; Meijer WG; Pruijt JFM; van Voorthuizen T; van Spronsen DJ; Rentinck M; Ten Oever D; Smit JM; Otten HM; van Gulik TM; Wilmink JW; Groot Koerkamp B; Klümpen H
    Acta Oncol; 2018 Jun; 57(6):807-812. PubMed ID: 29265948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter Phase II Trial of Axitinib Monotherapy for Gemcitabine-Based Chemotherapy Refractory Advanced Biliary Tract Cancer (AX-BC Study).
    Okano N; Furuse J; Ueno M; Morizane C; Yamanaka T; Ojima H; Ozaka M; Sasaki M; Takahara N; Nakai Y; Kobayashi S; Morimoto M; Hosoi H; Maeno S; Nagashima F; Ikeda M; Okusaka T
    Oncologist; 2021 Feb; 26(2):97-e201. PubMed ID: 33010112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irinotecan Plus Gemcitabine and Fluorouracil in Advanced Biliary Tract Cancer: A Retrospective Study.
    Endlicher E; Schnoy E; Troppmann M; Rogler G; Messmann H; Klebl F; Gelbmann C; Kullmann F
    Digestion; 2016; 93(3):229-33. PubMed ID: 27089254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic immunohistochemical biomarkers of chemotherapy efficacy in biliary tract cancer: A systematic review and meta-analysis.
    Belkouz A; Labeur TA; Dierks J; Dijk F; van Oijen MGH; Verheij J; van Gulik TM; van de Vijver MJ; Wilmink H; Punt CJA; Klümpen HJ
    Crit Rev Oncol Hematol; 2019 Sep; 141():82-94. PubMed ID: 31255992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
    Leone F; Marino D; Cereda S; Filippi R; Belli C; Spadi R; Nasti G; Montano M; Amatu A; Aprile G; Cagnazzo C; Fasola G; Siena S; Ciuffreda L; Reni M; Aglietta M
    Cancer; 2016 Feb; 122(4):574-81. PubMed ID: 26540314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study.
    Woo SM; Lee WJ; Han SS; Park SJ; Kim TH; Koh YH; Kim HB; Hong EK; Park JW; Kim CM
    Chemotherapy; 2012; 58(3):225-32. PubMed ID: 22831988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
    Furuse J; Okusaka T; Ohkawa S; Nagase M; Funakoshi A; Boku N; Yamao K; Yamaguchi T; Sato T
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):113-20. PubMed ID: 19404641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.